Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Immunoinformatics-Aided Design of a Peptide Based Multiepitope Vaccine Targeting Glycoproteins and Membrane Proteins against Monkeypox Virus.
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- المؤلفون: Akhtar, Nahid1 (AUTHOR); Kaushik, Vikas1 (AUTHOR) ; Grewal, Ravneet Kaur2 (AUTHOR); Wani, Atif Khurshid1 (AUTHOR); Suwattanasophon, Chonticha3 (AUTHOR); Choowongkomon, Kiattawee3 (AUTHOR) ; Oliva, Romina4 (AUTHOR); Shaikh, Abdul Rajjak2,3 (AUTHOR) ; Cavallo, Luigi5 (AUTHOR) ; Chawla, Mohit5 (AUTHOR)
- المصدر:
Viruses (1999-4915). Nov2022, Vol. 14 Issue 11, p2374. 18p.
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
Monkeypox is a self-limiting zoonotic viral disease and causes smallpox-like symptoms. The disease has a case fatality ratio of 3–6% and, recently, a multi-country outbreak of the disease has occurred. The currently available vaccines that have provided immunization against monkeypox are classified as live attenuated vaccinia virus-based vaccines, which pose challenges of safety and efficacy in chronic infections. In this study, we have used an immunoinformatics-aided design of a multi-epitope vaccine (MEV) candidate by targeting monkeypox virus (MPXV) glycoproteins and membrane proteins. From these proteins, seven epitopes (two T-helper cell epitopes, four T-cytotoxic cell epitopes and one linear B cell epitopes) were finally selected and predicted as antigenic, non-allergic, interferon-γ activating and non-toxic. These epitopes were linked to adjuvants to design a non-allergic and antigenic candidate MPXV-MEV. Further, molecular docking and molecular dynamics simulations predicted stable interactions between predicted MEV and human receptor TLR5. Finally, the immune-simulation analysis showed that the candidate MPXV-MEV could elicit a human immune response. The results obtained from these in silico experiments are promising but require further validation through additional in vivo experiments. [ABSTRACT FROM AUTHOR]
No Comments.